ICL ICL Group Ltd. IFRS Annual reports only
Agricultural Chemicals · NYSE · SEC CIK 941221 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.15B | $6.84B | $7.54B | $10.02B | $6.96B |
| Cost of revenue | $4.97B | $4.58B | $4.87B | $4.98B | $4.34B |
| Gross profit | $2.19B | $2.26B | $2.67B | $5.03B | $2.61B |
| R&D expense | $70.00M | $69.00M | $71.00M | $68.00M | $64.00M |
| SG&A expense | $299.00M | $259.00M | $260.00M | $291.00M | $276.00M |
| Operating income | $580.00M | $775.00M | $1.14B | $3.52B | $1.21B |
| Interest expense | $117.00M | $122.00M | $259.00M | $327.00M | $216.00M |
| Pretax income | $441.00M | $636.00M | $974.00M | $3.40B | $1.09B |
| Income tax | $161.00M | $172.00M | $287.00M | $1.19B | $260.00M |
| Net income | $226.00M | $407.00M | $647.00M | $2.16B | $783.00M |
| EBITDA | $1.31B | $1.39B | $1.68B | $4.01B | $1.69B |
| EPS (basic) | 0.18 | 0.32 | 0.50 | 1.68 | 0.61 |
| EPS (diluted) | 0.18 | 0.32 | 0.50 | 1.67 | 0.60 |
| Weighted avg. shares (diluted) | 1.29B | 1.29B | 1.29B | 1.29B | 1.29B |
| Balance sheet | |||||
| Cash & equivalents | $291.00M | $327.00M | $420.00M | $417.00M | $473.00M |
| Receivables | $1.36B | $1.26B | $1.38B | $1.58B | $1.42B |
| Inventory | $1.93B | $1.63B | $1.70B | $2.13B | $1.57B |
| Current assets | $4.16B | $3.59B | $4.03B | $4.55B | $3.91B |
| PP&E, netmay include right-of-use assets (IFRS) | $6.79B | $6.46B | $6.33B | $5.97B | $5.75B |
| Total assets | $12.41B | $11.32B | $11.63B | $11.75B | $11.08B |
| Current liabilities | $3.13B | $2.33B | $2.64B | $2.61B | $2.61B |
| Short-term debt | $437.00M | $108.00M | $575.00M | $199.00M | $250.00M |
| Long-term debt | $1.88B | $1.91B | $1.83B | $2.31B | $2.44B |
| Total debt | $2.32B | $2.02B | $2.40B | $2.51B | $2.69B |
| Total liabilities | $6.17B | $5.33B | $5.59B | $6.04B | $6.34B |
| Shareholders' equity | $5.98B | $5.72B | $5.77B | $5.46B | $4.53B |
| Net debt | $2.03B | $1.69B | $1.98B | $2.09B | $2.21B |
| Cash flow statement | |||||
| Operating cash flow | $1.06B | $1.47B | $1.71B | $2.13B | $1.06B |
| Investing cash flow | -$915.00M | -$694.00M | -$853.00M | -$747.00M | -$579.00M |
| Financing cash flow | -$195.00M | -$846.00M | -$837.00M | -$1.42B | -$244.00M |
| Depreciation & amortization | $726.00M | $610.00M | $536.00M | $498.00M | $484.00M |
| Stock-based compensation | — | — | — | $0 | $0 |
| Dividends paid | $224.00M | $251.00M | $474.00M | $1.17B | $276.00M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.